[Pharmacological and clinical profile of IFNbeta-1a (Avonex IM Injection Syringe 30 microg].
Sumino
Ruriko
R
ruriko.sumino@biogenidec.com
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D000818:Animals; D017951:Antigen Presentation / Q000187:drug effects; D000998:Antiviral Agents; D002455:Cell Division / Q000187:drug effects; D064420:Drug-Related Side Effects and Adverse Reactions; D015395:Histocompatibility Antigens Class I / Q000378:metabolism; D006801:Humans; D007273:Injections, Intramuscular; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D016393:Lymphoma, B-Cell / Q000473:pathology; D009103:Multiple Sclerosis / Q000188:drug therapy*; D018417:Th1 Cells / Q000276:immunology
D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D015395:Histocompatibility Antigens Class I; D016899:Interferon-beta; D000068556:Interferon beta-1a